Country: EU
Laboratories❯
The site is temporarily down due to maintenance. Sorry for the inconvenience.
The site is temporarily down due to maintenance. Sorry for the inconvenience.
The site is temporarily down due to maintenance. Sorry for the inconvenience.
The site is temporarily down due to maintenance. Sorry for the inconvenience.
Quality & Accuracy
Experience
The latest technologies
Speed &
Credibility
₾1,210.00
Study material: Venous blood
Response time (working day): 14
The test is done on an empty stomach: no
Home call service: YesClopidogrel genetic testing is a study that examines variants in the gene encoding the CYP2C19 enzyme and determines how effectively the body converts the medication (clopidogrel) into its active antiplatelet form.
CYP2C19The enzyme is a liver microsomal enzyme that is part of the cytochrome P450 enzyme family. This group of enzymes is involved in the metabolism of medications such as clopidogrel, propafenone, omeprazole, sertraline, citalopram, diazepam, and others.
The effectiveness of clopidogrel is significantly dependent on genetic variants of the CYP2C19 enzyme.
Variants in the CYP2C19 gene that reduce enzyme activity are responsible for clopidogrel resistance. Compared with individuals with normal metabolism, carriers of inactivating variants (especially in CYP2C19) have impaired inhibition of platelet aggregation and a higher risk of cardiovascular events (thrombosis, stroke, infarction).
In such patients, clopidogrel dosage adjustment (increase) or replacement with an alternative medication is often required.
Sample:VenousBlood
The results of the study provide the identification of the genotype encoding the CYP2C19 enzyme, which corresponds to different activities of the enzyme.
The activity of the CYP2C19 enzyme can be increased or decreased by concomitant medications, which directly affects the elimination of drugs that are metabolized by this enzyme.
Drugs that increase the activity of the CYP2C19 enzyme
Drugs that reduce CYP2C19 activity
The CYP2C19 enzyme is also involved in the metabolism of other drugs (statins, antidepressants, proton pump inhibitors).
The Clopidogrel test is a genetic test that checks for changes in the CYP2C19 gene. This gene codes for the cytochrome P450 2C19 enzyme, which is responsible for the metabolism of clopidogrel and other drugs. The test results help your doctor plan personalized treatment.
MedicationClasses,whichMetabolized by CYP2C19With enzyme
Antiplatelet agents → Clopidogrel (Plavix)
Anticonvulsants → Mephenytoin,Phenytoin,Diazepam,Primidone
Antidepressants → Amitriptyline,Citalopram, S-Citalopram,Clomipramine
Cytostatics → Cyclophosphamide
Antiretroviral drugs → Nelfinavir
Proton pump inhibitors → Lansoprazole,Pantoprazole,ომეპრაზოლი
Other drugs → Progesterone,Propranolol, R-Warfarin (Lessactiveisomer),Proguanil and others.
Patient preparation
Order all analyses online
Testing process
 |  |
| Purchase a test | Submission of material |
 |  |
| Results Online | Consult a doctor |
https://www.synevo.ro/shop/genotipare-cyp2c19/
https://medicover-genetics.com/product/pgx-cardiovascular/
Lee et al., CPIC Guideline for CYP2C19 Genotype and Clopidogrel Therapy: 2022 Update Clin Pharmacol Ther. 2022;112(5):959-967
Synevo Laboratory. Specific references to the working technology used. Ref Type: Catalog.
Laboratory Corporation of America. Directory of Services and Interpretive Guide. Clopidogrel CYP2C19 Genotyping. www.labcorp.com, 2010. Ref Type: Internet Communication.
Laboratory Corporation of America. Directory of Services and Interpretive Guide. Cytochrome P450 2C19 Genotyping. www.labcorp.com, 2009. Ref Type: Internet Communication.
Mayo Clinic. Mayo Medical Laboratories. Test Catalog: . Cytochrome P450 2C19 Genotyping by Sequence Analysis. www.mayomedicallaboratories.com. Ref Type: Internet Communication.
Quest Diagnostics. AccuTypeTM CP, Clopidogrel CYP2C19 Genotype (*2, *3, *4, *5, *6, *7, *8) . Clinical Focus. www.questdiagnostics.com. Reference Type: Internet Communication.
Simon T, Verstuyft C, Mary-Krause M, et al. Genetic Determinants of Response to Clopidogrel and Cardiovascular Events. In N Engl J Med, 2009, 360(4):363-375.
News and promotions
